Cannabis à usage médical : la France saura-t-elle combler son retard ? Bertrand Lebeau Leibovici Médecin addictologue Membre fondateur du GRECC Juin 2019 Agnès Buzin réussira-t-elle là où Bernard Kouchner puis Marisole Touraine ont échoué ? En queue de peloton européen sur la question de l’accès au cannabis à usage thérapeutique, la France, reconnait l’actuelle ministre de la Santé, a pris du « retard ». Pour le rattraper, elle a demandé à l’Agence Nationale de Sécurité du Médicament (ANSM) de créer un Comité Scientifique Spécialisé Temporaire (CSST) présidé par le professeur Nicolas Authier, qui dirige aussi la Commission des Stupéfiants et Psychotropes, dans le cadre de l’ANSM. L’enfant chéri de l’Agence a [...]
Lire la suiteThe Cannabis Conundrum : Thinking Outside the THC Box Sarah L. Hagerty, Sophie L. York Williams, Vijay A. Mittal, and Kent E. Hutchison The Journal of Clinical Pharmacology, 2015, 55, 8, 839–841 DOI: 10.1002/jcph.511 Keywords : cannabis, cannabinoids, D9-tetrahydrocannabinol (THC), cannabidiol (CBD), psychosis Despite nationwide movements to legalize and regulate cannabis, our understanding of its effects on human health is tenuous at best. Developing a solid evidence base regarding the health effects of cannabis is imperative given the momentum for legalization and the demand for sound regulatory practices. This present commentary will identify limitations with respect to previous research on cannabis, discuss the genesis and implications [...]
Lire la suiteTherapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain Julia De Ternay, Mickaël Naassila Mikail Nourredine, Alexandre Louvet, François Bailly, Guillaume Sescousse, Pierre Maurage, Olivier Cottencin, Patrizia Maria Carrieri and Benjamin Rolland Frontiers in Pharmacology, 2019, Volume 10, Article 627 doi : 10.3389/fphar.2019.00627 Abstract Background : Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim : To provide a rationale for [...]
Lire la suiteCannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]
Lire la suiteCannabis Companies Push F.D.A. to Ease Rules on CBD Products By Sheila Kaplan The New York Time, May 31, 2019 CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press Image CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditCreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press WASHINGTON — It was Hempy Pet CBD Soft Chews, Mile High Labs and Women Grow, [...]
Lire la suiteCannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. AJP in Advance, 2019, 1-12. doi: 10.1176/appi.ajp.2019.18101191 Objective : Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often [...]
Lire la suiteCannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders Jonathan L.C. Lee, Leandro J. Bertoglio, Francisco S. Guimarães and Carl W. Stevenson British Journal of Pharmacology, 2017, 174, 3242–3256 DOI : 10.1111/bph.13724 Abstract Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotionalmemories and inadequate treatment, often leading to symptom relapse. [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an anxiolytic drug Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, Adriana Cardoso de Oliveira e Silva, Jaime Eduardo Cecilio Hallak, José Alexandre S. Crippa, Antonio E. Nardi, Antonio Waldo Zuardi Revista Brasileira de Psiquiatria, 2012, 34 (Supl1), S104-S117 1516-4446 - ©2012 Elsevier Editora Ltda. All rights reserved. Abstract Objectives : To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. Method : The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI [...]
Lire la suiteFluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole, Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José, A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS ONE, Research Article, 2016 | DOI:10.1371/journal.pone.0158779 July 14, 2016 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials [...]
Lire la suitePharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview G. M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio and P. Brambilla Epidemiology and Psychiatric Sciences, 2018, 27, 327–335. © Cambridge University Press 2018 doi : 10.1017/S2045796018000239 Abstract : Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic [...]
Lire la suite